Comment on FR Doc # 2026-10128
American Pharmacists AssociationSupportTrade association
Summary: The American Pharmacists Association (APhA) supports the DEA's proposal to improve visibility into manufacturing timelines and distinguish between domestic and export markets to prevent drug shortages. However, they urge the DEA to also address downstream supply chain constraints, specifically requesting that the agency work with distributors to ensure that diversion-prevention measures do not inadvertently restrict access to medications for legitimate patients, such as those in hospice care.
Dear DEA Federal Register Representative/DPW,
The American Pharmacists Association (APhA) appreciates the opportunity to provide DEA comments on the “Revision of Applications for Manufacturing and Procurement Quotas,” notice of proposed rulemaking (NPRM).
APhA represents pharmacists, student pharmacists, and pharmacy technicians in all practice settings, including but not limited to community pharmacies, hospitals, long-term care facilities, specialty pharmacies, community health centers, physician offices, ambulatory clinics, managed care organizations, hospice settings, and government facilities. Our members strive to improve medication use, advance patient care, and enhance public health.
Full comments are attached.